Frazier Management LLC Syndax Pharmaceuticals Inc Transaction History

Frazier Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$14.84 - $22.15 $41.1 Million - $61.4 Million	-2,772,062 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$15.23 - $22.47 $24.1 Million - $35.6 Million	1,583,927 Added 133.31%	2,772,062 $60.7 Million
Q2 2021 Aug 11, 2021	SELL	$13.42 - $25.18 $3.31 Million - $6.22 Million	-246,910 Reduced 17.21%	1,188,135 $20.4 Million
Q1 2021 May 12, 2021	BUY	$19.28 - $24.59 $578,400 - $737,700	30,000 Added 2.14%	1,435,045 $32.1 Million
Q4 2020 Feb 11, 2021	BUY	$15.1 - $26.44 $1.28 Million - $2.25 Million	85,000 Added 6.44%	1,405,045 $31.2 Million
Q2 2020 Aug 04, 2020	BUY	$8.94 - $20.98 $2.94 Million - $6.91 Million	329,334 Added 33.24%	1,320,045 $19.6 Million
Q1 2020 May 13, 2020	BUY	$6.65 - $12.03 $6.59 Million - $11.9 Million	990,711 New	990,711 $10.9 Million

230

90M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $792M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

Stay updated on Frazier Management LLC with notifications on news.